MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting

Luis Ostrosky-Zeichner, Shmuel Shoham, Jose Vazquez, Annette Reboli, Robert Betts, Michelle A. Barron, Mindy Schuster, Marc A. Judson, Sanjay G. Revankar, Juan Pablo Caeiro, Julie E. Mangino, David Mushatt, Roger Bedimo, Alison Freifeld, Minh Hong Nguyen, Carol A. Kauffman, William E. Dismukes, Andrew O. Westfall, Jeanna Beth Deerman, Craig WoodJack D. Sobel, Peter G. Pappas

Research output: Contribution to journalArticlepeer-review

110 Scopus citations

Fingerprint

Dive into the research topics of 'MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting'. Together they form a unique fingerprint.

Medicine & Life Sciences